AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24445723 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg + amlodipine 5 mg
Number of subjects: 566
Study 24445723 — intervention group
Group type: COMPARATOR
Intervention: Placebo + amlodipine 5 mg
Number of subjects: 566
Study 24445723 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 566
Study 22370535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast dry syrup (PLK DS)
Number of subjects: 84
Study 22370535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 20687017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedated peroral EGD with normal-caliber endoscope
Number of subjects: 120
Study 20687017 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal EGD
Number of subjects: 120
Study 20687017 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-caliber endoscope
Number of subjects: 120
Study 20687017 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsedated transnasal EGD
Number of subjects: 120
Study 20687017 — intervention group
Group type: COMPARATOR
Intervention: Sedated peroral EGD
Number of subjects: 120
Study 18956509 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to social workers 3 days a week (Monday-Wednesday-Friday schedule)
Number of subjects: 0
Study 18956509 — intervention group
Group type: COMPARATOR
Intervention: Access to social workers 2 days a week (Tuesday-Thursday-Saturday schedule)
Number of subjects: 0
Study 15781511 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fentanyl 50 microg/mL (100 microg)
Number of subjects: 90
Study 15781511 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine 2% (40 mg)
Number of subjects: 90
Study 15781511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study 14569167 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET scanning
Number of subjects: 20
Study 14569167 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 20
Study 10759820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% cream with 2% glycolic acid applied twice daily for 12 weeks
Number of subjects: 19
Study 10759820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% cream with 2% glycolic acid plus salicylic acid peels every 3 weeks
Number of subjects: 19
Study 8689518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG)
Number of subjects: 143
Study 1355645 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol xinafoate (50 micrograms)
Number of subjects: 13
Study 1355645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 6389973 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antilymphocyte globulin (ALG) treatment for 21 days
Number of subjects: 94
Study 6389973 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ALG treatment)
Number of subjects: 94
Study 31650513 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and XEN implantation
Number of subjects: 31
Study 29589153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 or 10 mg, once daily orally)
Number of subjects: 446
Study 29589153 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-diabetic drugs other than SGLT-2 inhibitors)
Number of subjects: 446
Study 29589153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 446
Study 28003177 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth care program (website, mobile app, activity tracker)
Number of subjects: 308
Study 28003177 — intervention group
Group type: COMPARATOR
Intervention: Usual care (nonintervention standard website with digital information brochure)
Number of subjects: 308
Study 28003177 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth care program
Number of subjects: 308
Study 24553032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpronation technique
Number of subjects: 0
Study 24553032 — intervention group
Group type: COMPARATOR
Intervention: Supination-flexion technique
Number of subjects: 0
Study 23181618 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Group A, n=40)
Number of subjects: 80
Study 23181618 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (Group P, n=40)
Number of subjects: 80
Study 20859679 — intervention group
Group type: EXPERIMENTAL
Intervention: CellSearch® assay
Number of subjects: 254
Study 20859679 — intervention group
Group type: EXPERIMENTAL
Intervention: AdnaTest BreastCancer™
Number of subjects: 254
Study 20859679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests (CellSearch and AdnaTest)
Number of subjects: 254
Study 16784898 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg daily oral DHEA replacement for one year
Number of subjects: 225
Study 16784898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 15725968 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.)
Number of subjects: 293
Study 15725968 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.8 mg/kg/day)
Number of subjects: 293
Study 15725968 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg/day)
Number of subjects: 293
Study 15725968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 11888949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucus clearance device (MCD)
Number of subjects: 23
Study 11888949 — intervention group
Group type: COMPARATOR
Intervention: Sham MCD
Number of subjects: 23
Study 9464435 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography
Number of subjects: 43
Study 9464435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m DTPA renography
Number of subjects: 43
Study 9464435 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide computed glomerular filtration rate
Number of subjects: 43
Study 7762518 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 41
Study 7762518 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 41
Study 7762518 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 41
Study 2675432 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and Paracetamol
Number of subjects: 0
Study 2675432 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 53599 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon-arc photocoagulation treatment
Number of subjects: 76
Study 53599 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 76
Study 31269029 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training
Number of subjects: 12
Study 31269029 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 12
Study 28389025 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-implant group
Number of subjects: 20
Study 28389025 — intervention group
Group type: COMPARATOR
Intervention: 2-implant group
Number of subjects: 20
Study 26374825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg administered subcutaneously every 2 weeks
Number of subjects: 13
Study 26374825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23688301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime intensivist staffing (intervention)
Number of subjects: 1598
Study 23688301 — intervention group
Group type: COMPARATOR
Intervention: Nighttime coverage by daytime intensivists (control)
Number of subjects: 1598
Study 16468111 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular educational program for children with epilepsy and their parents (FAMOSES)
Number of subjects: 55
Study 16468111 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control group)
Number of subjects: 55
Study 12929752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT) using Foscan at a dose of 0.1 mg/kg 6 days before surgery and 652 nm red light at a dose of 10 J/cm2
Number of subjects: 9
Study 12929752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT)
Number of subjects: 9
Study 12929752 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study 11044498 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 381
Study 11044498 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with medroxyprogesterone acetate
Number of subjects: 381
Study 11044498 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with danazol
Number of subjects: 381
Study 11044498 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with nafarelin
Number of subjects: 381
Study 11044498 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 381
Study 11044498 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy after surgical treatment
Number of subjects: 381
Study 11044498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 8970686 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day oxandrolone
Number of subjects: 63
Study 8970686 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day oxandrolone
Number of subjects: 63
Study 8970686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 1483989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 112
Study 1483989 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet twice daily
Number of subjects: 112
Study 3883235 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.125 to 0.3 mg/d)
Number of subjects: 13
Study 3883235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30445008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole (60 mg)
Number of subjects: 115
Study 30445008 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg)
Number of subjects: 115
Study 30445008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 28546367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive PD dosage (> 30 L per day)
Number of subjects: 93
Study 28546367 — intervention group
Group type: COMPARATOR
Intervention: Minimal standard PD dosage (< 20 L per day)
Number of subjects: 93
Study 26661702 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic Trainers (ATs)
Number of subjects: 110
Study 26661702 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic Medical Residents
Number of subjects: 110
Study 23429038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 0.1% for 1 month (OBS1)
Number of subjects: 0
Study 23429038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 0.1% for 2 months (OBS2)
Number of subjects: 0
Study 23429038 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone 0.1% for 1 month (OFM)
Number of subjects: 0
Study 23429038 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1% for 1 month (ODM)
Number of subjects: 0
Study 23429038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 0.1%
Number of subjects: 0
Study 21160226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 78
Study 19843056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol clamping to maintain a pseudo-steady-state BrAC of 0.6 g l(‐1)
Number of subjects: 0
Study 17854250 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER (75 to 300 mg/day)
Number of subjects: 1096
Study 17854250 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1096
Study 17854250 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 1096
Study 15587094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.3 mg/kg)
Number of subjects: 40
Study 15587094 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.7 mg/kg)
Number of subjects: 40
Study 11522968 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue-directed biopsy
Number of subjects: 47
Study 11522968 — intervention group
Group type: COMPARATOR
Intervention: Conventional biopsy
Number of subjects: 47
Study 9544380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate one tablet qid, tetracycline 500 mg qid and metronidazole 400 mg tds (BTM)
Number of subjects: 80
Study 9544380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bd, amoxycillin 500 mg qid and metronidazole 400 mg tds (LAM)
Number of subjects: 80
Study 9544380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole sensitive strains of H. pylori
Number of subjects: 80
Study 9544380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole resistant strains of H. pylori
Number of subjects: 80
Study 8002529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at residual volume (RV)
Number of subjects: 0
Study 8002529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at relaxation volume (Vrel)
Number of subjects: 0
Study 8002529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at relaxation volume plus one-half of inspiratory capacity (Vrel + 1/2IC)
Number of subjects: 0
Study 8002529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 2462264 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fraction scheme of 5 times/week at 2 Gy/day for a total of 30 Gy/15 fractions (Group I)
Number of subjects: 80
Study 2462264 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 times/week at 4.5 Gy/day for a total of 22.5 Gy/5 fractions (Group II)
Number of subjects: 80
Study 2462264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times/week at 2 Gy/day twice a day at a minimum interval of 6 h for a total of 20 Gy/10 fractions (Group III)
Number of subjects: 80
Study 31838258 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus timing and coordination program
Number of subjects: 0
Study 31838258 — intervention group
Group type: COMPARATOR
Intervention: Standard strength, endurance, and flexibility program
Number of subjects: 0
Study 30936249 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary headache disorders (PHDs)
Number of subjects: 1346
Study 30936249 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine (a subset of PHDs)
Number of subjects: 1346
Study 30936249 — intervention group
Group type: EXPERIMENTAL
Intervention: PHDs in patients aged 18-44
Number of subjects: 1346
Study 30936249 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with PHDs
Number of subjects: 1346
Study 30936249 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up time intervals
Number of subjects: 1346
Study 28651151 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR with weekly schedule
Number of subjects: 0
Study 28651151 — intervention group
Group type: COMPARATOR
Intervention: IVR with daily schedule
Number of subjects: 0
Study 28651151 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS with weekly schedule
Number of subjects: 0
Study 28651151 — intervention group
Group type: COMPARATOR
Intervention: SMS with daily schedule
Number of subjects: 0
Study 28651151 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR (daily and weekly)
Number of subjects: 0
Study 28651151 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS (weekly)
Number of subjects: 0
Study 28651151 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR (hybrid protocol)
Number of subjects: 0
Study 26745106 — intervention group
Group type: EXPERIMENTAL
Intervention: Site specific biopsy using C‐NBI
Number of subjects: 500
Study 26745106 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 500
Study 23759267 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage containing 11% pea protein hydrolysate and 89% carbohydrates (79% maltodextrin and 21% sucrose), 400 mL the night before and 200 mL 3 h before surgery
Number of subjects: 22
Study 23759267 — intervention group
Group type: COMPARATOR
Intervention: Control group (6-8 h fast)
Number of subjects: 22
Study 22136113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pain management and training group (intervention)
Number of subjects: 0
Study 22136113 — intervention group
Group type: COMPARATOR
Intervention: Pain management group (control)
Number of subjects: 0
Study 19873688 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 746
Study 19873688 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 746
Study 19873688 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 8 mg/day
Number of subjects: 746
Study 17027427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal method (group discussion)
Number of subjects: 78
Study 17027427 — intervention group
Group type: COMPARATOR
Intervention: Delphi method (postal feedback only)
Number of subjects: 78
Study 17027427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal method
Number of subjects: 78
Study 17027427 — intervention group
Group type: COMPARATOR
Intervention: Delphi method
Number of subjects: 78
Study 15231922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander cardiopulmonary resuscitation (CPR)
Number of subjects: 599
Study 15231922 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessed arrests
Number of subjects: 599
Study 15231922 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of spontaneous circulation
Number of subjects: 599
Study 15231922 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival to hospital discharge
Number of subjects: 599
Study 15231922 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrest rhythms
Number of subjects: 599
Study 15231922 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic outcomes
Number of subjects: 599
Study 11106122 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate tablets of eniluracil (20 mg) and 5-FU (2 mg)
Number of subjects: 39
Study 11106122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined eniluracil/5-FU tablets (10/1 mg)
Number of subjects: 39
Study 11106122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined eniluracil/5-FU tablets (2.5/0.25 mg)
Number of subjects: 39
Study 11106122 — intervention group
Group type: COMPARATOR
Intervention: All treatments (A, B, C)
Number of subjects: 39
Study 9557071 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (PAF induced during TEP)
Number of subjects: 116
Study 8279247 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.7% end‐tidally (Group A)
Number of subjects: 95
Study 8279247 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion for 25 min and thereafter isoflurane (Group B)
Number of subjects: 95
Study 8279247 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion throughout the procedure (Group C)
Number of subjects: 95
Study 8279247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nauseated patients (total n = 24)
Number of subjects: 95
Study 8279247 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐nauseated patients in Group A
Number of subjects: 95
Study 2876923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol 30 mcg/kg twice daily
Number of subjects: 64
Study 2876923 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 75 mcg/kg three times daily
Number of subjects: 64
Study 2876923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol (various doses 10 to 60 mcg/kg)
Number of subjects: 64
Study 2876923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol 30 and 40 mcg/kg twice daily
Number of subjects: 64
Study 31715628 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by trained family doctors
Number of subjects: 272
Study 31715628 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 272
Study 29356102 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure 1 (rotation of the lens in three meridians: 0°, 60°, and 120°)
Number of subjects: 18
Study 29356102 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure 2 (rotation of the optotypes in the same meridians)
Number of subjects: 18
Study 29356102 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure 1
Number of subjects: 18
Study 29356102 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure 1 and Procedure 2
Number of subjects: 18
Study 27109262 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to induce refixation saccades into gathered fashion
Number of subjects: 16
Study 24118860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 24118860 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234
Study 24118860 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle
Number of subjects: 3234
Study 22633722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous contrast alone (IV)
Number of subjects: 227
Study 22633722 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and oral contrast (IVO)
Number of subjects: 227
Study 20977016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hellison's Teaching Personal and Social Responsibility Model applied in physical education classes
Number of subjects: 30
Study 20977016 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 30
Study 18546896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.2‐0.7 microg x kg(‐1) x hr(‐1)
Number of subjects: 66
Study 18546896 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PRO) 1‐3 mg x kg(‐1) x hr(‐1)
Number of subjects: 66
Study 15802769 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 15802769 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0
Study 15802769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (general)
Number of subjects: 0
Study 15802769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (long-term treatment)
Number of subjects: 0
Study 11850308 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance and functional training
Number of subjects: 28